Adolescent obesity has emerged as a major public health challenge worldwide, precipitating early cardiometabolic complications and psychosocial distress. Although lifestyle modifications form the foundation of management, sustained weight reduction remains difficult for most pediatric patients. Therefore, pharmacotherapeutic interventions have gained substantial clinical attention. Recent evidence highlights the expanding utility of liraglutide in adolescent obesity as an adjunct to structured behavioral changes. While randomized controlled trials established regulatory approval, real-world observational data offer vital insights into true clinical practice, tolerability, and adherence in diverse populations.

Clinical Need and Real-World Evaluation of Liraglutide in Adolescent Obesity

Pediatric obesity affects millions of young individuals, accelerating the onset of type 2 diabetes, dyslipidemia, hypertension, and steatotic liver disease. Despite intensive behavioral counseling, biological counter-regulatory systems often hinder sustained weight loss. Consequently, clinicians require safe and effective adjunctive medical therapies to modify disease trajectories before irreversible vascular damage occurs. Randomized clinical trials demonstrated that glucagon-like peptide-1 receptor agonists provide effective appetite regulation by enhancing satiety and delaying gastric emptying. However, controlled trials enforce strict protocols that do not always mirror day-to-day outpatient practice. In everyday pediatric clinics, dose titration, patient adherence, and comorbidity management often differ substantially from clinical trial settings. To address these evidence gaps, a multicenter prospective observational study examined the real-world performance of liraglutide across fourteen hospitals and clinics in Taiwan. The investigators followed adolescents over twenty-six weeks to evaluate practical safety and anthropometric trajectories under routine medical oversight. This investigation provides crucial data regarding how youth tolerate daily incretin therapy outside controlled trial environments, helping providers set realistic expectations for families.

Patient Baseline Profiles and Dosing Dynamics in Routine Practice

The multicenter prospective study evaluated forty-one adolescents receiving once-daily subcutaneous liraglutide between February 2024 and March 2025. Males comprised 53.7% of the cohort, with an overall mean participant age of 13.9 years. At treatment initiation, participants exhibited severe excess weight, with a baseline mean body weight of 88.5 kg and a mean body mass index of 33.4 kg/m2. Notably, 46.3% of participants presented with documented hepatic impairment, reflecting the high prevalence of pediatric steatotic liver disease. Dosing patterns in this real-world setting revealed fascinating deviations from formal clinical trial algorithms. In formal trials, clinicians titrate patients up to the target maintenance dose of 3.0 mg per day. Conversely, participants in this cohort received a mean daily dose of 1.4 mg and reached a mean maximum dose of 1.8 mg over an average duration of 128.3 days. Furthermore, only 14.4% of participants escalated therapy to the full 3.0 mg daily dose. Thus, treating clinicians frequently settled on lower maintenance doses, prioritizing tolerability while maintaining steady progress.

Weight Loss Trajectory and Metabolic Outcomes Over 26 Weeks

Despite utilizing lower average doses than registered clinical trials, the prospective cohort achieved statistically and clinically meaningful reductions in excess adiposity. Specifically, participants demonstrated significant improvements across primary anthropometric parameters at week 13 and week 26. Mean body weight decreased by 2.7 kg, reflecting an immediate therapeutic response that persisted across follow-up intervals. Moreover, patients experienced a significant reduction in body mass index of 1.3 kg/m2, alongside marked drops in body mass index standard deviation scores. Because adolescents experience continuous linear growth, reductions in standard deviation scores serve as the gold-standard metric for pediatric weight loss efficacy. These results confirm that lower daily doses can effectively curtail excessive weight accretion and facilitate meaningful fat mass reduction. Additionally, stabilizing weight during critical pubertal development produces profound downstream cardiometabolic dividends. Modest weight reductions alleviate hepatic fat accumulation and enhance insulin sensitivity. Therefore, real-world liraglutide administration reliably mitigates metabolic risks in adolescents, even when clinical circumstances preclude full titration to maximum doses.

Safety Profile and Tolerability of Incretin Therapy in Youth

Safety and tolerability remain central considerations when initiating pharmacotherapy in young patients. In this prospective evaluation, the overall incidence of adverse events reached 19.5%, and adverse drug reactions occurred in 9.8% of patients. Importantly, all reported events were mild in severity, and no serious adverse reactions arose during the observation period. Gastrointestinal symptoms represented the most frequent complaints, followed by minor injection site-related reactions. Patients occasionally reported transient nausea, mild dyspepsia, and self-limiting abdominal discomfort during initial dosage titration. Most remarkably, zero participants discontinued therapy due to drug intolerance or adverse side effects. This finding contrasts favorably with several previous studies where gastrointestinal intolerance led to noticeable treatment dropout. Clinicians achieved high persistence by utilizing gradual dose escalation and pragmatic dose adjustments. Furthermore, the high proportion of patients with baseline hepatic impairment experienced no exacerbations of liver dysfunction. Thus, routine clinical monitoring confirms that liraglutide possesses an exceptionally reassuring safety profile in adolescents.

Practical Implications for Pediatric and Adolescent Obesity Care

The real-world findings from this prospective multicenter study offer invaluable guidance for clinicians managing pediatric and adolescent weight disorders. First, the data prove that individualized dosing represents a viable and pragmatic strategy in outpatient pediatrics. Clinicians do not necessarily need to push every adolescent to the maximum 3.0 mg daily dose to achieve meaningful clinical benefit. Instead, intermediate doses between 1.2 mg and 1.8 mg can stimulate sufficient satiety while reducing medication burden and gastrointestinal side effects. Second, proactive counseling regarding healthy eating patterns and hydration can virtually eliminate treatment discontinuation caused by nausea. Third, because nearly half of these adolescents presented with underlying liver disease, early pharmacotherapy provides a critical opportunity to arrest hepatic pathology. Multidisciplinary care, combining nutritional guidance, physical activity, and medical therapy, remains paramount for durable lifestyle change. Looking ahead, pediatricians and endocrinologists must collaborate closely with families to maintain realistic goals. By integrating real-world insights into everyday practice, healthcare teams can optimize therapeutic success and improve lifelong health trajectories.

Frequently Asked Questions

What dosage of liraglutide is typically effective in adolescents?

Clinical trials often titrate patients toward 3.0 mg daily, but real-world practice reveals distinct patterns. In routine pediatric management, many adolescents achieve meaningful clinical progress on intermediate doses averaging 1.4 mg to 1.8 mg per day. Consequently, physicians often personalize dose escalation based on individual tolerability and therapeutic response. This flexible titration strategy minimizes uncomfortable gastrointestinal side effects while sustaining satisfactory weight control and adherence throughout treatment.

What are the most frequent adverse reactions observed in youth?

Gastrointestinal symptoms represent the primary adverse reactions during glucagon-like peptide-1 therapy. Specifically, youth most commonly experience transient nausea, mild vomiting, abdominal discomfort, and occasional diarrhea during early initiation or dosage adjustment. Injection site reactions may also occur infrequently. Fortunately, real-world data indicate that these adverse effects remain overwhelmingly mild and self-limiting. As a result, very few adolescents require permanent treatment discontinuation when clinicians provide proactive dietary guidance and gradual titration.

How should clinicians monitor adolescents receiving glucagon-like peptide-1 agonists?

Clinicians must implement regular follow-up evaluations every twelve to thirteen weeks to monitor anthropometric parameters, linear growth, and pubertal development. In addition, providers should assess gastrointestinal tolerability, hydration status, and psychological well-being during every routine visit. Because many adolescents present with hepatic steatosis or early metabolic dysregulation, periodic monitoring of liver enzymes, glycemic indices, and lipid profiles is vital. Ultimately, multidisciplinary lifestyle reinforcement remains essential alongside pharmacotherapy for long-term health.

Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Chiu CF et al. A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan. Obes Res Clin Pract. 2026 Sep 15. doi: undefined. PMID: 42744726.
2. Kelly AS, Auerbach P, Barrientos-Perez M, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117-2128.
3. Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640.